Omalizumab is an anti-IgE therapeutic monoclonal IgG1 antibody that inhibits the interaction of IgE with Fc∊RI and is approved for the treatment of moderate-to-severe persistent allergic asthma and chronic idiopathic urticaria (Holgate et al., 2005 ▸; Sussman et al., 2014 ▸). Here, IGHE is linked to chronic idiopathic urticaria.